Stock Markets May 13, 2026 08:54 AM

UnitedHealth Shares Slip After Federal Pause on New Medicare Hospice and Home-Health Enrollments

Administration's anti-fraud moratorium gives CMS time to review spending and issue guidance on hospice and home health programs

By Hana Yamamoto UNH CHE

UnitedHealth Group shares declined after the federal government announced a temporary nationwide moratorium on Medicare enrollments for new home healthcare and hospice providers. The pause, put forward by an anti-fraud task force led by Vice President JD Vance, is intended to allow the Centers for Medicare & Medicaid Services time to evaluate Medicare spending on these services and to craft additional guidance amid concerns about rapidly established fraudulent operators.

UnitedHealth Shares Slip After Federal Pause on New Medicare Hospice and Home-Health Enrollments
UNH CHE

Key Points

  • UnitedHealth stock fell 1% after the administration announced a temporary nationwide moratorium on Medicare enrollments for new home-health and hospice providers.
  • The moratorium, driven by Vice President JD Vance's anti-fraud task force, gives CMS time to assess hospice and home health spending and to draft additional guidance.
  • Major operators in the home health and hospice markets include BrightSpring Health Services, Matrix Medical Network, UnitedHealth, and VITAS Healthcare (a Chemed subsidiary) - indicating potential operational and policy impacts across insurers and service providers.

UnitedHealth Group (NYSE:UNH) stock dipped 1% on Wednesday after reports that the Trump administration will temporarily stop Medicare enrollments for newly formed home healthcare and hospice providers. The halt follows an announcement from an anti-fraud task force operating under Vice President JD Vance.

Officials said the nationwide moratorium is intended to provide the Centers for Medicare & Medicaid Services (CMS) with a pause to review hospice and home health expenditures under Medicare and to produce further guidance. According to a senior administration official, the move targets concerns over how quickly fraudulent home health and hospice businesses can be set up and begin billing Medicare.

Data cited from the Medicare Payment Advisory Commission shows the scale of the programs under review: in 2024, 1.8 million Medicare beneficiaries received hospice care at a reported cost of $28.3 billion, while 2.7 million patients received home healthcare at a reported cost of $16 billion.

The U.S. home health market includes large operators such as BrightSpring Health Services, private equity-backed Matrix Medical Network, and UnitedHealth. In the hospice segment, VITAS Healthcare - a subsidiary of Chemed Corporation - is listed among top providers.

This moratorium follows prior actions by the administration to curb alleged healthcare fraud. Earlier this year, Medicare enrollments by suppliers of durable medical equipment were paused in February. The administration has also criticized certain Democratic-led states, naming California and Minnesota as examples it says have not done enough to combat fraud, and it increased oversight of hospices in Georgia and Ohio during the prior year.

Industry groups estimate tens of billions of dollars are lost annually in the United States to healthcare fraud, a drain that organizations warn raises costs for patients and employers, according to the National Health Care Anti-Fraud Association.

The temporary nationwide pause on new enrollments is designed to allow CMS to re-evaluate spending patterns and to develop additional guidance for the hospice and home-health sectors, while the anti-fraud task force and federal oversight continue to probe vulnerabilities in provider enrollment and billing.

Risks

  • Temporary enrollment pause could slow onboarding of legitimate new providers in the home health and hospice sectors, affecting access and market dynamics - impacting healthcare providers and insurers.
  • Increased federal oversight and prior pauses in enrollments (for durable medical equipment suppliers) signal regulatory uncertainty that could affect provider revenues and contract flows across the broader healthcare services supply chain.
  • Ongoing scrutiny focused on states and specific hospices introduces policy and compliance risk for providers operating in jurisdictions noted for weaker anti-fraud controls, with potential downstream effects on payers and employers bearing higher costs.

More from Stock Markets

Amazon Debuts 'Alexa for Shopping' to Personalize Purchases Across App, Web and Echo Show May 13, 2026 Daiwa narrows stance on AMD after rapid rally, lifts price target to $500 May 13, 2026 UnitedHealth Retreats After Record High as Investors Take Profits; Optum Rx Unveils New Pricing Model May 13, 2026 Red Cat Holdings Shares Slide After Public Offering Priced at $9.40 May 13, 2026 Compass Pathways Shares Climb After Q1 Beat and Regulatory Momentum May 13, 2026